MarketBeat
13 Jul 2026, 16:02 UTC · 10w ago
Verdict
Headline takes no side. We score QTTB +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Q32 Bio reported positive Phase 2a results for bempikibart, with 40% of the mITT population achieving the SALT-20 registration endpoint.
More positive than 98% of claims this week
Bempikibart demonstrated a favorable safety profile with no Grade 3 or higher adverse events and no safety-related discontinuations.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
The company intends to initiate a registration-directed (Phase 3) program in severe and very severe alopecia areata in the first half of 2027.
More positive than 79% of claims this week
Q32 Bio forecasts a total U.S. market opportunity of at least $5 billion by 2037 for the treatment of alopecia areata.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company reported positive Phase 2a results for bempikibart with strong efficacy and a favorable safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
−21.8%
Price is moving against the score
$8.77 vs $11.21 close before publication (Jul 10) · not market-adjusted
QTTB chart →
